openPR Logo
Press release

Global Liquid Biopsy Market Opportunity & Technology Outlook 2020 Report

05-07-2018 08:46 AM CET | Health & Medicine

Press release from: Kuick Resarch

Global Liquid Biopsy Market Opportunity & Technology Outlook

“Global Liquid Biopsy Market Opportunity & Technology Outlook 2020” Report Highlights:

* Introduction & Mechanism of Action of Liquid Biopsy
* Diagnostic Technological Advancement Supplementing Liquid Biopsy Market
* Clinical Investigation Using Cell-Free Circulating Tumor DNA for Different Indications
* Combinational Analysis on the Working of Circulating Tumor Cells & Cell-Free Tumor DNA
* Market Share of Different Liquid Biopsy Techniques
* Business Model of Liquid Biopsy Market

Download Report Sample Weblink:

https://www.kuickresearch.com/report-Global-Liquid-Biopsy-Market-Opportunity-&-Technology-Outlook-2020.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

1. Introduction to Liquid Biopsy: A Non-Invasive, Game-Changer Diagnostic Tool



2. Mechanism of Action: Major Components of Liquid Biopsy

2.1 Circulating Tumor Cells

2.1.1 Parameters Guiding Circulating Cell Tumors

2.2 Circulating Tumor Nucleic Acids (ctNA)

2.2.1 Cell-Free Tumor DNA

2.2.2 Other Circulatory Tumor Nucleic Acid: microRNA, mRNA & Long Non-Coding RNAs

2.3 Exosomes



3. Circulatory Tumor Cells: A Snapshot; Its History, Biologics, Selection Method, Detection Procedures, Enrichment Procedures, Analysis & Disease Monitoring

3.1 The History & Introduction

3.2 The Selection Methods

3.3 The Analysis Methodologies

3.4 The Scope of Disease Monitoring

3.5 The Biologics of Circulatory Tumor Cells



4. Diagnostic Technological Advancement Supplementing Liquid Biopsy Market

4.1 Glimpses to the Next Generation Sequencing Techniques

4.2 Methodologies Involved in the Next Generation Sequencing

4.2.1 Genomics

4.2.2 Transcriptomics

4.2.3 Epigenomics

4.3 Flowchart Depicting Genomic Analysis Using Next Generation Sequencing

4.3.1 A Basic Workflow of Next Generation Sequencers

4.3.2 Integrated Data Analysis

4.4 Pricing Implications of Next Generation Sequencing On the Liquid Biopsy Market



5. Clinical Investigation Using Cell-Free Circulating Tumor DNA for Different Indications

5.1 Lung Cancer

5.2 Breast Cancer

5.3 Colorectal Cancer

5.4 Melanoma

5.5 Gastric Cancer

5.6 Prostate Cancer

5.7 Brain Cancer

5.8 Detection & Monitoring of Type 1 Diabetes

5.9 Pancreatic Cancer

5.10 Renal Cancer

5.11 Retinoblastoma



6. Combinational Analysis on the Working of Circulating Tumor Cells & Cell-Free Tumor DNA



7. Business Model of Liquid Biopsy Market: A Hotbed for Start-Ups and Venture Capital Funding



8. Other Market Modalities Associated With Liquid Biopsy

8.1 Accreditation through Clinical Laboratory Improvement Amendments (CLIA) Testing: Green Signal for Liquid Biopsy

8.2 The Impact of Service Providers in Liquid Biopsy Market

8.3 The Role of Liquid Biopsy In The Light Of Insurance Associated Issues



9. Liquid Biopsy Market Share in North America, Europe, Asia- Pacific & Rest of the World

9.1 North America

9.2 Europe

9.3 Asia-Pacific

9.4 Rest of the World

9.4.1 Africa

9.4.2 South America

9.4.3 Middle East



10. Market Drivers: Clinical Utilities of Liquid Biopsy. Why Do We Need Them?

10.1 Help Monitor Minimal Residue Disease

10.2 Help Track Emergence of Drug Resistance

10.3 Liquid Biopsy Used As a Predictive & Pharmacodynamic Biomarker

10.3.1 Cell-Free Tumor DNA as Predictive Biomarker

10.3.2 Cell-Free Tumor DNA as Pharmacodynamic Biomarker



11. Market Trends in Liquid Biopsy. Is The Era Of Tissue Biopsy Coming To An End?



12. Market Share of Different Liquid Biopsy Techniques



13. Market Challenges: Liquid biopsy, A Revolution in Cancer Diagnosis; a Myth or a Reality?

13.1 Complex Immuno-Biochemical Mechanism of Cancer Cells

13.2 The Risk of False Positive Liquid Biopsy Test

13.3 The Risk of False Negative Liquid Biopsy Test

13.4 Inconclusive Nature of Cancer Biomarkers

13.5 Lack of Standardized Protocols

13.6 Business Model Based Challenges

13.7 Issues Related To Regulatory Framework



14. Conclusion: Liquid Biopsy; Real-Time & Revolutionary Novel Diagnostic Tool



15. Competitive Landscape

15.1 AdnaGen (QIAGEN)

15.2 Agena Bioscience

15.3 Angle

15.4 ApoCell

15.5 Biocept

15.6 BioFluidica

15.7 Bio-Rad Laboratories

15.8 Boreal Genomics

15.9 Chronix Biomedical

15.10 Clearbridge BioMedics

15.11 Cynvenio

15.12 Cytotrack

15.13 Epic Sciences

15.14 Exosome Diagnostics

15.15 Fluidigm

15.16 Fluxion Biosciences

15.17 Genomic Health

15.18 Guardant Health

15.19 HansaBiomed

15.20 Horizon Discovery

15.21 iCellate

15.22 Illumina

15.23 Inivata

15.24 Janssen Diagnostics

15.25 Molecular MD

15.26 Myriad Genetics

15.27 Natera

Figure 1-1: Limitations of Tissue Biopsy

Figure 1-2: Hallmarks of Cancer Cells

Figure 1-3: Advantages of Liquid Biopsy

Figure 2-1: Major Components of Liquid Biopsy

Figure 2-2: Properties of Circulatory Tumor Cells

Figure 2-3: Techniques Guiding Circulating Cell Tumors Separation

Figure 2-4: Cell-Free Tumor DNA

Figure 2-5: Other Circulatory Tumor Nucleic Acid

Figure 2-6: Exosomes Based Liquid Biopsy

Figure 3-1: Introduction to Circulatory Tumor Cells

Figure 3-2: Selection Methods of Circulating Tumor Cells

Figure 3-3: The Analysis Methodologies for Circulatory Tumor Cells

Figure 3-4: The Scope of Disease Monitoring With Circulatory Tumor Cell

Figure 3-5: The Biologics of Circulatory Tumor Cells

Figure 4-1: Methodologies Involved In the Next Generation Sequencing

Figure 4-2: Genomics Attributes of Next Generation Sequencing

Figure 4-3: Proteomic Attributes of Next Generation Sequencing

Figure 4-4: Epigenomic Attributes of Next Generation Sequencing

Figure 4-5: Flowchart Depicting Genomic Analysis Using Next Generation Sequencing

Figure 4-6: Pricing Implications of Next Generation Sequencing On the Liquid Biopsy Market

Figure 5-1: Liquid Biopsy for Detection of Lung Cancer

Figure 5-2: Liquid Biopsy for Detection of Breast Cancer

Figure 5-3: Liquid Biopsy for Detection of Colorectal Cancer

Figure 5-4: Liquid Biopsy for Detection of Melanoma

Figure 5-5: Liquid Biopsy for Detection of Gastric Cancer

Figure 5-6: Liquid Biopsy for Detection of Prostate Cancer

Figure 5-7: Liquid Biopsy for Detection of Brain Cancer

Figure 5-8: Detection & Monitoring of Type 1 Diabetes

Figure 5-9: Liquid Biopsy for Detection of Pancreatic Cancer

Figure 5-10: Liquid Biopsy for Detection of Renal Cancer

Figure 5-11: Liquid Biopsy for Detection of Retinoblastoma

Figure 6-1: Circulating Tumor Cells & Cell-free Tumor DNA

Figure 6-2: Differential Study of Circulating Tumor Cells & Cell-free Tumor DNA

Figure 7-1: Liquid Biopsy for Start-Ups & Venture Capitalists; Favorable Factors

Figure 8-1: Accreditation Program for Liquid Biopsy

Figure 8-2: Service Providers in Liquid Biopsy Market

Figure 8-3: Liquid Biopsy & Insurance Coverage Plans

Figure 9-1: Liquid Biopsy Market in North America

Figure 9-2: Liquid Biopsy Market in Europe

Figure 9-3: Liquid Biopsy Market in Asia-Pacific Region

Figure 9-4: Liquid Biopsy Market in Rest of the World

Figure 10-1: Liquid Biopsy in Monitoring Minimal Residual Disease

Figure 10-2: Liquid Biopsy in Tracking Emergence of Drug Resistance

Figure 10-3: Liquid Biopsy as a Predictive & Pharmacodynamic Biomarker

Figure 11-1: Market Trends in Liquid Biopsy

Figure 12-1: Liquid Biopsy Market by Technique

Figure 13-1: Market Challenges Associated With Liquid Biopsy

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Liquid Biopsy Market Opportunity & Technology Outlook 2020 Report here

News-ID: 1040949 • Views:

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Biopsy

Biopsy Devices Market Overview by Breast Biopsy, Lung Biopsy, Prostate Biopsy to …
Download Free PDF Sample Papers Now at Biopsy Devices Market https://www.reportsnreports.com/contacts/requestsample.aspx?name=1159148 . Biopsy devices market report analyzes various types of biopsy devices in market and their adoption patterns. It aims at estimating market size and future growth potential of biopsy devices market for different segments such as product, guidance technique, application, end user, and region. Global biopsy devices market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East
Biopsy Device Market to Increase to US$ 2,621 Mn by 2026 | Guidance System (Ster …
Key players focussing on strategic M&A for amplified market shares Patients are increasingly preferring minimally invasive surgical procedures in order to avoid conventional surgical complications and side-effects, promoting sales of biopsy devices, leading to the growth of the biopsy devices globally. In addition to enabling the accurate diagnosis, a biopsy device assures minimal patient discomfort and trauma. This is identified to be a major factor impacting the popularity of biopsy, and
Breast Biopsy Market Report 2018: Segmentation by Product (Vacuum Assisted Biops …
Global Breast Biopsy market research report provides company profile for Hologic Inc., Leica Biosystems Nussloch GmbH (Devicor Medical Products, Inc.), C. R. Bard, Inc., Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule medical Devices LLC. and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume,
Biopsy Devices Market Report 2018: Segmentation by Product (Core Needle Biopsy, …
Global Biopsy Devices market research report provides company profile for C. R. Bard, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Cook Group Incorporated (U.S.), Devicor Medical Products, Inc., (Leica Biosystems) (Germany), Argon Medical Devices (U.S.) and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth
Needle Biopsy Industry 2018, Market Structure - By Type Fine-Needle Aspiration B …
Needle Biopsy Market information: by type (fine-needle aspiration biopsy, core needle biopsy, vacuum-assisted biopsy, image-guided biopsy) by utility (disposable, reusable), by applications (tumor, infection, Inflammation, others) - Global Forecast till 2023. Considering all these factors the market for Needle Biopsy is expected to reach $ 677 million by the end of 2023, this market is projected to be growing at a CAGR of ~ 5.2 % during 2017-2023. KEY PLAYERS OF NEEDLE
Global Breast Biopsy Devices Market In Japan: By Product - Biopsy Needles, Biops …
Researchmoz added Most up-to-date research on "Global Breast Biopsy Devices Market In Japan: By Product - Biopsy Needles, Biopsy Tables, Guidance Systems & Localization Wires" to its huge collection of research reports. The global Breast Biopsy Devices market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2017, growing at a CAGR of XX% between 2016 and 2022. Japan plays an